Journal of Antimicrobial Chemotherapy · 2020 · 36 citations · 20 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntimicrobial Susceptibility TestingBeta-lactam ResistanceCarbapenem ResistanceMultidrug ResistanceAcinetobacter Baumannii InfectionAcinetobacter Baumannii ResistanceBeta-lactamase InhibitorsCarbapenem AntibioticsCarbapenemase EnzymesClass A Beta-lactamasesIntrinsic ActivityResistance In Clinical Isolates
BACKGROUND: Durlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii. Currently, there is widespread resistance caused by multiple β-lactamases including class A carbapenemases and class C and class D enzymes. The addition of durlobactam to sulbactam restores in vitro activity against MDR A. baumannii that possess multiple β-lactamases. OBJECTIVES: Previously, susceptibility data for sulbactam/durlobactam were limited to isolates from patients in Western countries. This study was undertaken to determine the activity of sulbactam/durlobactam against A. baumannii isolated from patients in mainland China. METHODS: Nine hundred and eighty-two recent A. baumannii clinical isolates were collected from 22 sites across mainland China during 2016-18. The isolates were collected from lower respiratory tract, intra-abdominal, urinary tract and skin and skin structure infections. The in vitro activities of sulbactam/durlobactam and comparators were determined by broth microdilution. RESULTS: The addition of durlobactam restored the activity of sulbactam against the majority of the strains tested. The MIC90 of sulbactam/durlobactam was 2 mg/L for all A. baumannii, compared with 64 mg/L for sulbactam alone. The MIC90 of sulbactam/durlobactam of 2 mg/L remained unchanged for 831 carbapenem-resistant isolates. Colistin was the only comparator with comparable activity (MIC90 = 1 mg/L). CONCLUSIONS: This study demonstrated the potential utility of sulbactam/durlobactam for the treatment of infections caused by A. baumannii in China.
20
Kristine M. Hujer, Andrea M. Hujer, Edward Hulten et al. · Antimicrobial Agents and Chemotherapy · 2006 · 481 citations · Full text
Xavier Corbella, Abelardo Montero, Miquel Pujol et al. · Journal of Clinical Microbiology · 2000 · 346 citations · Full text
Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations